DRD2 and myalgic encephalomeyelitis/chronic fatigue syndrome: The authors wrote: “... a growing body of evidence suggests that ME/CFS involves inflammation of the brain... dopamine D2 receptor agonists have been shown to mediate neuroinflammation, microglial activation... this suggests that dopamine-modulating drugs like aripiprazole may lead to clinical improvement in fatigue and cognitive symptoms in ME/CFS...” (49).